SynthesisOncotarget2016

HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.

Qian-Qian Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.